PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY W/HIGH-DOSE CYCLOPHOSPHAMIDE PLUS DOXORUBICIN (AC) VS SEQUENTIAL DOXORUBICIN FOL BY CYCLOPHOSPHAMIDE (A-C) IN HIGH RISK BREAST CANCER PATIENTS WITH 0-3 POSITIVE NODES (INTERGROUP, CALGB 9394):